HMG Peptide

Human Menopausal Gonadotropin contains both FSH and LH activity. It stimulates Sertoli cells (FSH) and Leydig cells (LH) simultaneously, valuable for gonadal function and spermatogenesis research.

Human Menopausal Gonadotropin (HMG) is a purified urinary extract obtained from postmenopausal women, containing equimolar bioactivity of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), typically standardized at 75 IU of each per ampoule. Both gonadotropins are heterodimeric glycoproteins composed of a common alpha subunit (92 amino acids) and a hormone-specific beta subunit that confers receptor specificity. The combined FSH/LH activity profile distinguishes HMG from recombinant single-hormone preparations and forms the basis of its utility in gonadotropin receptor and ovarian/testicular signaling research.

FSH Receptor (FSHR) Signaling

FSH binds the FSH receptor (FSHR), a class A G-protein-coupled receptor (GPCR) expressed predominantly on ovarian granulosa cells and testicular Sertoli cells. Receptor activation couples primarily to Gαs, stimulating adenylyl cyclase and elevating intracellular cyclic AMP (cAMP). Downstream protein kinase A (PKA) activation phosphorylates CREB and drives transcription of aromatase (CYP19A1), inhibin-B, and FSHR itself. In granulosa cells, this cascade promotes follicular recruitment, granulosa proliferation, and conversion of androgens to estradiol. FSHR signaling also engages PI3K/AKT and ERK1/2 pathways, contributing to cell survival and differentiation.

LH Receptor (LHCGR) Signaling

The LH component of HMG binds the luteinizing hormone/choriogonadotropin receptor (LHCGR), expressed on ovarian theca cells, granulosa cells of pre-ovulatory follicles, corpus luteum, and testicular Leydig cells. LHCGR activation similarly couples to Gαs/cAMP/PKA, upregulating steroidogenic acute regulatory protein (StAR), CYP17A1, and CYP11A1 — enzymes that mediate androgen synthesis from cholesterol. In theca cells, this provides the androgen substrate that FSH-induced aromatase converts to estradiol — the classical "two-cell, two-gonadotropin" model of ovarian steroidogenesis. In Leydig cells, LHCGR drives testosterone biosynthesis.

Combined FSH/LH Activity in Research Models

The dual-receptor activity of HMG makes it a valuable tool for studying coordinated gonadotropin signaling that mimics endogenous pituitary output more closely than single-hormone recombinant preparations. Research has shown that LH activity in HMG preparations supplements thecal androgen production, supporting estradiol output particularly in models of low endogenous LH (e.g., hypogonadotropic states or GnRH-antagonist co-treatment). The urinary source also contributes hCG-derived LH bioactivity, since postmenopausal urine is enriched in hCG isoforms that bind LHCGR with similar affinity but longer plasma half-life than pituitary LH.

Glycosylation and Bioactivity

Both FSH and LH carry N-linked oligosaccharide chains that strongly influence receptor binding kinetics, circulating half-life, and intracellular signaling bias. Urinary HMG contains a heterogeneous mixture of glycoforms — including acidic, highly sialylated isoforms — which produce longer in vivo persistence compared to less-glycosylated pituitary forms. Researchers studying glycoform-specific receptor activation, biased agonism at FSHR/LHCGR, or comparative pharmacology between urinary and recombinant gonadotropins frequently use HMG as a reference standard.

HMG is a biologically derived glycoprotein preparation, not a defined small-molecule peptide, and its characterization reflects this complexity. The following table summarizes the physicochemical properties relevant to research handling and experimental design.

Researchers should note that HMG is dose-standardized by bioactivity (IU) rather than mass, because the glycoform heterogeneity inherent to urinary preparations means specific activity varies between lots. Comparative experiments should reference WHO International Standards and document lot numbers. Unlike defined recombinant gonadotropins, HMG batches may contain minor co-purified urinary proteins, which is relevant for high-sensitivity assays or proteomic studies.

Human Menopausal Gonadotropin is a heterogeneous glycoprotein preparation requiring careful handling to preserve the tertiary structure and glycosylation patterns essential for receptor binding activity. Unlike small synthetic peptides, HMG's bioactivity depends on intact heterodimeric assembly of α and β subunits stabilized by non-covalent interactions and intramolecular disulfide bridges.

Reconstitution Protocol

1. Equilibrate the lyophilized vial to room temperature (15-25°C) for 15-20 minutes prior to opening. Cold vials promote moisture condensation, which can compromise the lyophilized cake.
2. Select appropriate diluent. Use sterile bacteriostatic water for injection (0.9% benzyl alcohol) or sterile sodium chloride 0.9% for research applications. Bacteriostatic water is preferred for multi-day reconstituted storage.
3. Calculate concentration. A standard reconstitution is 75 IU + 1 mL diluent = 75 IU/mL, or 150 IU + 1 mL = 150 IU/mL for higher-concentration research models.
4. Inject diluent slowly down the side of the vial wall — never directly onto the lyophilized powder. Direct impact can shear glycoprotein structure.
5. Gently swirl the vial in a circular motion until fully dissolved (typically 30-60 seconds). The solution should appear clear and colorless.
6. DO NOT shake or vortex. Mechanical agitation generates foam and air-water interfaces that denature glycoproteins, causing irreversible loss of FSH and LH bioactivity.
7. Inspect visually. Discard if particulates, cloudiness, or discoloration are observed.

Compound-Specific Notes

• Glycoprotein fragility: HMG's sialic acid residues are critical for in vivo half-life and receptor binding. Avoid pH extremes (maintain pH 6.5-7.5) and elevated temperatures during handling.
• Adsorption losses: Glycoprotein hormones can adsorb to glass and plastic surfaces. Use low-binding polypropylene tubes when transferring small volumes, or include 0.1% human serum albumin in research dilutions to minimize losses.
• Sterile technique: Glycoprotein solutions are excellent microbial growth substrates. Use aseptic technique and avoid repeated needle entries beyond what is necessary.

All handling must be performed in appropriate laboratory settings by qualified research personnel. This material is intended exclusively for in vitro and preclinical research applications.

Proper storage of Human Menopausal Gonadotropin is essential for preserving FSH and LH bioactivity. As a heterodimeric glycoprotein mixture, HMG is more thermolabile than synthetic peptides and requires stricter temperature control to prevent subunit dissociation, deglycosylation, and aggregation.

Lyophilized Powder Storage

• Long-term (>30 days): Store at -20°C in a non-frost-free freezer. Properly stored lyophilized HMG retains bioactivity for 24-36 months when protected from moisture and light.
• Short-term (up to 30 days): Store at 2-8°C (standard refrigeration) in original sealed vial with desiccant.
• Transit/ambient: Lyophilized HMG tolerates room temperature (15-25°C) exposure for up to 7 days without significant bioactivity loss, but cumulative ambient exposure should be minimized.
• Light protection: Store in original amber or foil-wrapped vials. UV exposure can degrade aromatic residues and disulfide bridges.

Reconstituted Solution Storage

• 2-8°C (refrigerated): Use within 28 days when reconstituted with bacteriostatic water. Use within 24-48 hours if reconstituted with sterile saline (no preservative).
• -20°C (frozen aliquots): Single-use aliquots can be stored frozen for up to 3 months. Avoid repeated freeze-thaw cycles, which cause subunit dissociation and bioactivity loss of 15-30% per cycle.

Stability Considerations

• Glycosylation integrity: Sialic acid residues on FSH and LH glycans are essential for receptor binding affinity. Repeated temperature cycling promotes desialylation.
• Disulfide bond preservation: Both α and β subunits contain multiple intrachain disulfide bonds. Reducing agents (DTT, β-mercaptoethanol) must be strictly excluded from buffers.
• Aggregation risk: Glycoproteins are prone to aggregation at elevated concentrations (>1 mg/mL) or under mechanical stress. Maintain dilute working concentrations and avoid agitation.
• pH stability window: HMG is most stable at pH 6.5-7.5. Acidic conditions (<pH 5) promote irreversible subunit dissociation.

For optimal research reproducibility, prepare single-use aliquots upon initial reconstitution and document storage history.